| Name | Title | Contact Details |
|---|
Idenix Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Idenix Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on Idenix Pharmaceuticals, Inc. at www.idenix.com
The Health and Rejuvenation Center is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
F-D-C Reports, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Tucson Medical Center, licensed at 607 beds, has been Tucson`s locally governed nonprofit regional hospital for 70 years. TMC is Southern Arizona`s leading provider for emergency care and pediatric care (including Tucson`s first Pediatric Emergency Department), with top-notch intensive care units for adults, children and newborns. Other specialty areas include women`s, maternity, cardiovascular, orthopaedic, neuroscience, hospice, imaging and senior services. TMC earned certification as a Primary Stroke Center, accreditation as a Chest Pain Center, and the Gold Plus Achievement Award for stroke programs from the American Heart Association/American Stroke Association. TMC is also a recipient of the AHA/ASA`s Target: Stroke Honor Roll. TMC HealthCare is Southern Arizona`s locally governed nonprofit system, the corporate entity that includes Tucson Medical Center and Saguaro Physicians.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.